Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Injection Therapy of Allogeneic Stem Cells in Ischemic No-option Patients
2019-002511-26Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Nov 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of CSCC_ASC in Ischemic congestive heart failure (ICM-HF) and heart failure (HF) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in LV end-systolic volume at 12 months. Started Nov 2019; status: terminated.
02
Drugs
CSCC_ASC
03
Conditions
Ischemic congestive heart failure (ICM-HF)heart failure (HF)
Beyond the preview
Go deeper on 2019-002511-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002511-26.